Abstract
This study was designed to determine if GR 32191 a thromboxane A2 receptor antagonist, would lower blood pressure in patients with hypertension and renal artery stenosis. Eight patients with unilateral atheromatous renal artery stenosis and hypertension were studied in a double-blind, single dose, placebo controlled, crossover study. The results show that, GR 32191, given orally, in doses of 20 mg and 40 mg, does not reduce the blood pressure to any clinically important degree.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Imanishi M., Kawamura M., Akabane S., Matsushima Y., Kuramochi M., Ito K., Ohta M., Kimura K., Takamiya M., Omae T. Aspirin lowers blood pressure in patients with renovascular hypertension. Hypertension. 1989 Nov;14(5):461–468. doi: 10.1161/01.hyp.14.5.461. [DOI] [PubMed] [Google Scholar]
- Lumley P., White B. P., Humphrey P. P. GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro. Br J Pharmacol. 1989 Jul;97(3):783–794. doi: 10.1111/j.1476-5381.1989.tb12017.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Marshall F. I., Hagen S., Mahaffy R. G., Petrie J. C., Roy-Chaudhury P., Russell I. T., Webster J. Percutaneous transluminal angioplasty for atheromatous renal artery stenosis--blood pressure response and discriminant analysis of outcome predictors. Q J Med. 1990 May;75(277):483–489. [PubMed] [Google Scholar]